|
| 1994 | |
| 1994_1_A: |
Journal of Medical Screening |
| 1994_1_B: |
Screening for malignant melanoma |
| 1994_2_A: |
Medical screening: the way forward |
| 1994_3_A: |
Screening for neuroblastoma in children |
| 1994_3_B: |
Why screen for HIV infection in pregnancy? |
| 1994_4_A: |
What are we screening for? |
| 1994_4_B: |
Is screening for ovarian cancer worthwhile? |
| 1994_4_C: |
"Opportunistic" screening |
|
| 1995 | |
| 1995_1_A: |
The risk figure of 1/270 |
| 1995_1_B: |
Information leaflets |
| 1995_2_A: |
The health service and personal costs of screening |
| 1995_4_A: |
Breast screening in Britain |
|
| 1996 | |
| 1996_1_A: |
What is case-finding? |
| 1996_1_B: |
Should testicular self examination be recommended? |
| 1996_2_A: |
What is genetic screening anyway? |
| 1996_4_A: |
Prevention of blindness: a lost opportunity |
| 1996_4_B: |
Screening for haemochromatosis |
|
| 1997 | |
| 1997_1_A: |
Why the term "carrier screening" should be abandoned |
| 1997_1_B: |
Epidemiological clues from screening |
| 1997_2_A: |
Case-control studies of the efficacy of screening for cancer: can we earn them some respect? |
| 1997_2_B: |
Screening for Huntington disease and certain other dominantly inherited disorders: a case for preimplantation genetic testing |
| 1997_2_C: |
Systematic reviews of screening |
| 1997_3_A: |
Screening for neuroblastoma in children |
| 1997_4_A: |
National Institutes of Health consensus development conference statement on genetic testing for cystic fibrosis |
|
| 1998 | |
| 1998_1_A: |
Should we screen for factor V Leiden? |
| 1998_1_B: |
Down's syndrome screening in twins |
| 1998_1_C: |
Voluntary registration of unreported randomised trials: an initiative from medical editors |
| 1998_3_A: |
Current state of second trimester screening for Down's syndrome |
| 1998_4_A: |
The first report of the National Screening Committee |
| 1998_4_B: |
Antenatal screening for HIV in the UK: what is to be done? |
|
| 1999 | |
| 1999_1_A: |
Prenatal cytogenetic diagnosis |
| 1999_2_A: |
Cervical screening programme, England: 1997-98 |
| 1999_3_A: |
Reporting of screening results |
| 1999_4_A: |
Preventing neural tube defects: a major success story, with a chapter yet to be written |
|
| 2000 | |
| 2000_1_A: |
Populist instead of professional |
| 2000_1_B: |
Screening for hypothyroidism in adults: supporting data from two population studies |
| 2000_1_C: |
Screening for type II diabetes mellitus |
| 2000_1_D: |
The challenge of preventive medicine in 2000 |
| 2000_2_A: |
When screening is not enough |
| 2000_3_A: |
Spiral computed tomography screening |
| 2000_3_B: |
In search of better ways to transmit information about screening tests |
|
| 2001 | |
| 2001_1_A: |
The definition of screening |
| 2001_2_A: |
Screening newborn infants for cystic fibrosis |
| 2001_2_B: |
The threat to the use of records and stored blood samples in medical screening research |
| 2001_2_C: |
Consenting adults |
| 2001_3_A: |
JMS Online at a screen near you: www.jmedscreen.com |
| 2001_3_B: |
The number needed to screen - an adaptation of the number needed to treat |
| 2001_4_A: |
All screening is universal |
|
| 2002 | |
| 2002_1_A: |
The Medical Screening Society |
| 2002_2_A: |
Could HPV testing become the sole primary cervical screening test? |
| 2002_2_B: |
Outcome events in studies of diagnostic or screening tests |
| 2002_2_C: |
Faecal occult blood screening for colorectal cancer |
| 2002_2_D: |
Screening for neuroblastoma in children |
| 2002_3_A: |
The National Down Syndrome Cytogenetic Register (NDSCR) |
| 2002_4_A: |
Seeking other disorders within antenatal serum screening programmes for Down's syndrome |
|
| 2003 | |
| 2003_1_A: |
Under new management! Medical Screening Society buys Journal of Medical Screening |
| 2003_2_A: |
Safety First: choices in antenatal screening for Down's syndrome |
| 2003_3_A: |
Prenatal screening for cystic fibrosis in the United States - time to re-evaluate implementation policies |
| 2003_4_A: |
How frequently should cervical screening be conducted - important new evidence |
|
| 2004 | |
| 2004_1_A: |
Live long and prosper: a mass strategy for treating the factors associated with ischaemic heart disease and stroke |
| 2004_2_A: |
NHS breast screening: the progression from one to two views |
| 2004_2_B: |
Is cascade testing a sensible method of population screening? |
| 2004_4_A: |
The vagaries of prostate cancer screening |
|
| 2005 | |
| 2005_1_A: |
An epidemic averted through medical screening |
| 2005_2_A: |
Couple screening to avoid thalassemia: successful in Iran and instructive for us all |
| 2005_2_B: |
Screening, surgical repair, and the management of abdominal aortic aneurisms |
| 2005_2_C: |
Medical screening society working groups |
| 2005_3_A: |
Screening for oesophageal cancer: is it timely or premature? |
| 2005_4_A: |
Prophylactic vaccines for human papillomavirus: a bright future for cervical cancer prevention |
|
| 2006 | |
| 2006_1_A: |
Screening for chronic glaucoma |
| 2006_2_A: |
When screening is still not enough |
| 2006_2_B: |
Our health, our care, our say |
| 2006_2_C: |
NHS breast screening: a model national programme |
| 2006_3_A: |
Information leaflets in medical screening |
|
| 2007 | |
| 2007_1_A: |
Paying for publication |
| 2007_4_A: |
Screening: a step too far. A matter of concern |
|
| 2009 | |
| 2009_3_A: |
What now on screening for prostate cancer? |
|
| 2010 | |
| 2010_2_A: |
ACOG guidelines on cervical screening: a step in the right direction |
| 2010_2_B: |
Colorectal cancer prevention through screening: population acceptance of flexible sigmoidoscopy |
| 2010_4_A: |
Hypothyroidism: detecting and treating early symptoms as the body's energy rheostat is slowly turned down |
|
| 2011 | |
| 2011_1_A: |
Discounting the value of life |
| 2011_2_A: |
Genetic testing |
| 2011_2_B: |
Genetic profiling tests in screening for cardiovascular disease |
| 2011_2_C: |
Vitamin D and rickets: much has been accomplished, but there is room for improvement |
| 2011_3_A: |
Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST) |
| 2011_3_B: |
Some clarity in the management of DCIS in breast cancer screening |
| 2011_4_A: |
Estimates of the potential risk of radiation-related cancerfrom screening in the UK |
| 2011_4_B: |
Screening for cardiovascular disease: concerns with a Norwegian proposal |
| 2011_4_C: |
Screening to detect Lynch syndrome and prevent hereditary cancers in relatives |
|
| 2012 | |
| 2012_2_A: |
Colonoscopy as a primary screening method? |
| 2012_2_B: |
Maternal plasma DNA: a major step forward in prenatal testing |
| 2012_3.1_A: |
The benefits and harms of mammographic screening for breast cancer: building the evidence base using service screening programmes |
| 2012_4_A: |
The Canadian recommendations on screening for type 2 diabetes |
|
| 2013 | |
| 2013_2_A: |
The press, press releases, and raising unwarranted expectations |
|
| 2014 | |
| 2014_1_A: |
Cochrane report on lowering blood pressure |
| 2014_2_A: |
Recent results from the two Canadian Breast Screening Trials |
|
| 2015 | |
| 2015_3_A: |
Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage |
| 2015_4_A: |
Informed decision-making and breast cancer screening |
|
| 2016 | |
| 2016_2_A: |
The NHS Health Checks programme: A better alternative |
| 2016_3_A: |
Discounting financial costs and health benefits in public health programmes |
|
| 2017 | |
| 2017_2_A: |
Sharing clinical trial data |
| 2017_4_A: |
Screening and preventive medication |
|
| 2018 | |
| 2018_3_A: |
Medical Screening Society members' talks |
|
2019 | |
| 2019_1_A: |
Conflating screening detection rates with the uptake of further testing: A potential source of confusion |
| 2019_2_A: |
Risk stratification in breast screening: A word of caution |
|
2020 | |
| 2020_2_A: |
Flexible use of flexible sigmoidoscopy |
|
2021 | |
| 2021_1_A: |
NHS announces a pilot of a blood test for early detection of many cancers |
